Features of central neurotransmission in animals in conditions of dietary magnesium deficiency and after its correction

Neuroscience and Behavioral Physiology

Volumn 39, Issue 7, 2009, Pages 645-653

  Spasov, A A ^a   Iezhitsa, I N ^a   Kravchenko, M S ^a   Kharitonova, M V ^a  

^a VOLGOGRAD STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

5 hydroxytryptophan; Apomorphine; Arecoline; Clonidine; Magnesium; Magnesium deficiency; Nicotine; Pyridoxine; Rats

Indexed keywords

5 HYDROXYTRYPTOPHAN; ACETYLCHOLINE; APOMORPHINE; ARECOLINE; CLONIDINE; MAGNE B6; MAGNESIUM; MAGNESIUM ASPARTATE; MAGNESIUM CHLORIDE; MAGNESIUM CITRATE; NEUROTRANSMITTER; NICOTINE; NORADRENALIN; PHENAMINE; PYRIDOXINE; SEROTONIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLINERGIC TRANSMISSION; CONTROLLED STUDY; CONVULSION; DRUG EFFICACY; HYPERKINESIA; INDUCED HYPOTHERMIA; LATENT PERIOD; MAGNESIUM DEFICIENCY; MALE; NEUROTRANSMISSION; NONHUMAN; NORADRENERGIC SYSTEM; RAT; SEROTONINERGIC TRANSMISSION; STEREOTYPY; TREATMENT RESPONSE; TREMOR;

ANIMALS; ASPARTIC ACID; CATIONS, DIVALENT; DIET; MAGNESIUM; MAGNESIUM CHLORIDE; MAGNESIUM DEFICIENCY; MALE; MOTOR ACTIVITY; NEUROTRANSMITTER AGENTS; RATS; REACTION TIME; SEIZURES; STEREOTYPED BEHAVIOR; VITAMIN B 6; VITAMINS;

EID: 68349157537     PISSN: 00970549     EISSN: 1573899X     Source Type: Journal    
DOI: 10.1007/s11055-009-9182-y     Document Type: Article

References (36)

1. N. I. Andreeva, Methodological Recommendations for the Study of the Antidepressant Activity of Pharmacological Substances. Handbook for the Experimental (Preclinical) Study of New Pharmacological Substances [in Russian], Moscow (2000).
2. O. A. Gromova, T. V. Avdeenko, and E. M. Burtsev, "Magnesium deficiency in children with minimal brain dysfunction and its correction with Magne B 6, " Klin. Farmakol. Terapiya, 7, No. 3, 52-57 (1998).
3. V. V. Men'shikov, Laboratory Methods for Clinical Studies [in Russian], Meditsina, Moscow (1987).
4. A. A. Spasov, I. N. Iezhitsa, M. V. Kharitonova, and M. S. Kravchenko, "Effects of magnesium salts on the formation of depression-like behavior and anxiety in animals in conditions of dietary magnesium deficiency," Zh. Vyssh. Nerv. Deyat. imeni I. P. Pavlova (in press).
5. N. Amyard, A. Leyris, C. Monier, H. Frances, R. G. Boulu, and J. G. Henrotte, "Brain catecholamines, serotonin and their metabolites in mice selected for low (MGL) and high (MGH) blood magnesium levels," Magnes. Res., 8, No. 1, 5-9 (1995).
6. P. Bac, N. Pages, C. Herrenknecht, C. Dewulf, P. Binet, and J. Burlach, "Effect of various serotoninergically induced manipulations on audiogenic seizures in magnesium-deficient mice," Magnes. Res., 7, No. 2, 107-115 (1994).
7. R. M. Bergman, A. Cappiello, A. Anand, D. A. Oren, G. R. Heininger, D. S. Charney, and J. H. Krystal, "Antidepressant effects of ketamine in depressed patients," Biol. Psychiatry, 47, 351-354 (2000).
8. A. Bloc, E. Bugnard, and Y. Dunant, "Acetylcholine synthesis and quantal release reconstituted by transfection of mediatophore and choline acetyl transferase cDNAs," Eur. J. Neurosci., 11, 1523-1534 (1999).
9. G. Choinard, L. Beauclair, R. Geiser, and P. Etienne, "A pilot study of magnesium aspartate hydrochloride (Magnesiocard) as a mood stabilizer for rapid cycling bipolar affective disorder patients," Prog. Neuropsychopharmacol. Biol. Psychiatr, 14, 171-180 (1990).
10. J. G. Chutkow and G. M. Tyce, "Brain norepinephrine, dopamine, and 5-hydroxytryptamine in magnesium-deprivation encephalopathy in rats," J. Neural Transm., 44, No. 4, 297-302 (1979).
11. I. M. Cox, M. J. Campbell, and D. Dowson, "Red blood cell magnesium and chronic fatigue syndrome," Lancet, 337, 757-760 (1991).
12. S. Decollogne, A. Tomas, C. Lecerf, E. Adamowicz, and M. Seman, "NMDA receptor complex blockade by oral administration of magnesium: Comparison with MK-801," Pharmacol. Biochem. Behav., 58, No. 1, 261-268 (1997).
13. J. Durlach, "Données actuelles sur les mécanismes de synergie entre vitamine B 6 et magnesium," J. Méd. Besançon, 5, 349-359 (1968).
14. J. Durlach, Magnesium in Clinical Practice, John Libbey, London (1988).
15. J. Durlach, V. Durlach, P. Bac, and M. Bara, "Magnesium and therapeutics," Magnes. Res., 7, No. 3-4, 313-328 (1994).
16. H. El-Beheiry and E. Puil, "Effects of hypomagnesia on transmitter actions in neocortical slices," Brit. J. Pharmacol., 101, No. 4, 1006-1010 (1990).
17. M. Firoz and M. Graber, "Bioavailability of US commercial magnesium preparations," Magnes. Res., 14, No. 4, 257-262 (2001).
18. J. E. Holl, A. V. Resurreccion, L. E. Park, and W. O. Caster, "Barbiturate and amphetamine activity in rats fed a magnesium-deficient diet," Res. Commun. Pathol. Pharmacol., 22, No. 3, 501-512 (1978).
19. I. N. Iezhitsa, A. A. Spasov, M. S. Kravchenko, M. V. Kharitonova, A. A. Ozerov, and I. Yu. Pavlova, "Comparative study of magnesium salts' bioavailability in rats fed with magnesium-deficient diet. Abstracts of the 11th International Magnesium Symposium & Joint Meeting of the Japanese Society for Magnesium Research," J. Jap. Soc. Magnes. Res., 25, No. 2, 99-153 (2006).
20. R. A. Janssen and C. Y. Niemegeers, "Is it possible to predict the clinical effects of neuroleptic drugs from animal data? Part IV," Arzneimittel. Forsch., 17, No. 7, 841-854 (1967).
21. J. D. Kanofsky and R. Sandyk, "Magnesium deficiency in chronic schizophrenia," Int. J. Neurosci., 61, No. 1-2, 87-90 (1991).
22. G. K. Korov, N. J. Birch, P. Steadman, and R. G. Ramsey, "Plasma magnesium levels in a population of psychiatric patients: Correlations with symptoms," Neuropsychobiology, 30, No. 2-3, 73-78 (1994).
23. J. Levine, D. Stein, A. Rapoport, and L. Kurtzman, "High serum and cerebrospinal fluid Ca/Mg ratio in recently hospitalized acutely depressed patients," Neuropsychobiology, 39, 63-70 (1999).
24. 2+ of NMDA responses in spinal cord neurons," Nature, 309, 261-263 (1984).
25. M. F. McCarty, "High-dose pyridoxine as an 'anti-stress' strategy," Med. Hypotheses, 54, No. 5, 803-807 (2000).
26. R. M. Morris, "Brain and CSF magnesium concentrations during magnesium deficit in animals and humans: Neurological symptoms," Magnes. Res., 5, 303-313 (1992).
27. M. Mousain-Bosc, M. Roche, A. Polge, D. Pradal-Prat, J. Rapin, and J. P. Bali, "Improvement of neurobehavioral disorders in children supplemented with magnesium-vitamin B 6 I. Attention deficit hyperactivity disorders," Magnes. Res., 19, No. 1, 46-52 (2006).
28. H. Murck, "Atypical depression spectrum disorder-neurobiology and treatment," Acta Neuropsychiatrica, 15, 227-241 (2003).
29. H. Murck, "Magnesium and affective disorders," Nutr. Neurosci., 5, 375-389 (2002).
30. C. S. Paulose, K. Dakshinamurti, S. Packer, and N. L. Stephens, "Sympathetic stimulation and hypertension in the pyridoxine-deficient adult rat," Hypertension, 11, No. 4, 387-391 (1988).
31. 6 status in the rat," J. Amer. Coll. Nutr., 16, No. 4, 352-356 (1997).
32. E. Poleszak and G. Nowak, "Magnesium in pathophysiology and therapy of affective disorders," J. Element (Biuletyn Magnezologiczny), 11, No. 3, 389-397 (2006).
33. H. H. Rasmussen, P. B. Mortensen, and I. W. Jensen, "Depression and magnesium deficiency," Int. J. Psychiatry Med., 19, No. 1, 57-63 (1989).
34. S. K. Sharma and K. Dakshinamurti, "Effects of serotonergic agents on plasma prolactin levels in pyridoxine-deficient adult male rats," Neurochem. Res., 19, No. 6, 687-692 (1994).
35. N. Singewalk, C. Sinner, A. Hetzenauer, S. B. Sartori, and H. Murck, "Magnesium-deficient diet alters depression- and anxiety-related behavior in mice-influence of desipramine and Hypericum perforatum extract," Neuropharmacology, 47, 1189-1197 (2004).
36. P. Skolnick, "Modulation of glutamate receptors: Strategies for the development of novel antidepressants," Amino Acids, 23, 153-159 (2002).